

Date of submission: October 31, 2024

То,	To,
The Secretary	The Secretary
Listing Department	Listing Department
BSE Limited	National Stock Exchange of India
Department of Corporate Services	Limited
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai – 400 001	Mumbai – 400 051
Scrip Code – 539551(EQ), 975516	Scrip Code- NH

Dear Sir/Madam,

Sub: Investor Presentation for the guarter and half year ended September 30, 2024

With reference to the subject, please find enclosed the Investor Presentation for the quarter and half year ended September 30, 2024.

Kindly take the above information on record.

Thanking you

Yours faithfully For **Narayana Hrudayalaya Limited**

Sridhar S. Group Company Secretary, Legal & Compliance Officer

Encl.: as above



Narayana

Earnings Update Q2 FY25

	Торіс	Slide No.
	Our Footprint	03
	Narayana Health at a Glance	04
	Q2 FY25 Highlights	05
Index	Сарех	13
	NH Integrated Care and Insurance	14
	Digital Transformation Initiatives	15
	Narayana Health ESG Vision – "Health For All"	16
	Shareholding Pattern	17

-

2



South

Hospitals - 6 | Heart Centres - 2 | Clinics - 12 Operational beds - 2,006 (Hospitals) - 128 (Heart Centres)

East

Hospitals - 7 | Clinics - 4| Dialysis Centre - 1 Operational beds - 1,994

North Hospitals – 4 | Clinics - 1 Operational beds: 1,200

West Hospitals - 2 Operational beds - 351



Facility Details	No. of Facilities	Operational Beds	Image: 6,260Capacity Beds
Owned / Operated Hospitals ⁽¹⁾	19	5,551	5.5 Mns ⁽²⁾ Average Effective Capital Cost per
Heart Centres	2	128	Operational Bed
Clinics and Dialysis Centre	18	0	Total 19,760 Clinical : 12,040
Cayman Islands	1	110	Non-clinical : 7,720
Healthcare Facilities	40	5,789	4,243 Doctors

(1) Owns the P&L responsibility

(2) Based on (Gross Block for Fixed Assets (adjusted for non-cash government grant provision impact, non-cash financial lease impact for Dharamshila unit, non-cash EPCG license impact)+ Capital Work in Progress (CWIP)) / Number of operational beds as of Sept 30th 2024 but excluding Cayman facility

- Narayana Institute of Cardiac Sciences (NICS), Bengaluru has performed 113 Robotic Cardiac Surgeries in the quarter.
- Rabindranath Tagore International Institute of Cardiac Science (RTIICS), Kolkata has performed Embolization of High Flow Arterio-Venous Malformation of Hand on a 64-year-old presented with gradually progressive pulsatile swelling along palmar aspect of left hand since childhood, high flow malformation (AVM), multiple radial artery feeders and early filling of prominent draining vein. Percutaneous embolization of nidus was done with 3 injections of Glue + Lipiodol.
- Mazumdar Shaw Medical Centre (MSMC), Bengaluru has successfully performed the following procedures during the quarter:
 - Karnataka's first Ankle Replacement Surgery
 - First ever Radiofrequency Ablation of anomalous foetus (monochorionic, diamniotic twin) at 22wk gestation, where the anomalous foetus had complex Congenital Heart disease (TOF with PS); the procedure potentially avoided monochorionicity specific complications like Twin anaemia polycythaemia sequence, a form of twin-to-twin transfusion syndrome & IUGR, allowing the healthy foetus to grow to full term safely
 - Transabdominal USG guided therapeutic Amnioinfusion intermittently in a primigravida with oligohydramnios, a very rare procedure – enabling a 400-gm foetus at 23-week gestation to reach 2.4 kg at 36-week term gestation for safe delivery.




Clinical &

Operational


- Consolidated operating revenues of **INR 14,000** in Q2 FY25, an increase of 7.3% YoY and 4.4% QoQ.
- Consolidated EBITDA of **INR 3,320 Mns** in Q2 FY25 at margin of 23.7%, and consolidated PAT of **INR 1,988 Mns** for Q2 FY25 at a margin of 14.2%.


Financial Performance Consolidated Total Borrowings less Cash & Bank Balance and Investments of INR 2,684 Mn as on 30th Sept 2024, i.e. net debt to equity ratio of 0.08 (Out of which, debt worth US\$ 81.5 Mns is foreign currency denominated).

India Operations – Revenue (Q2 FY25)




International Revenue (INR Mns)







Integrated Care - NHIC and NHIL (INR Mns)




India Operations – Revenue Mix (Q2 FY25)





Payor-Profile^(4,7)



Owned Hospitals ⁽¹⁾

- Operated Hospitals ⁽²⁾
- Heart Centres
- Other Anciliary Businesses ⁽³⁾

- Cardiac Sciences
- Oncology
- Neuro Sciences
- Others

- Medicine and GI sciences
- Renal Sciences
- Orthopaedics

- Domestic Walk-in patients
- Insured Patients ⁽⁵⁾
- Schemes ⁽⁶⁾
- International patients

(1) NH owns on freehold basis and operates with the P&L responsibility


- (2) NH operates the hospitals on rental/revenue sharing basis and owns the P&L responsibility
- (3) Includes clinics and dialysis centres etc
- (4) As percentage of operating revenue, excluding NHIC


(5) Insured Patients include Insurance-covered patients, corporate patients (including PSU's under rack rates)

(6) Schemes include CGHS, ESIS, other state government schemes

(7) Percentages might not add up to 100% due to rounding off

Operational Review – India (Q2 FY25)






Patient Footfalls (IP & OP)^(1,3) 710 685 '000 650 OP IP 64 59 Q2 FY24 Q1 FY25 Q2 FY25

ICU Occupied Bed Days

62




(1) OP figures include day-care business.

(2) ARPOB for the period Q2 FY25 was INR 15.0 Mns as against INR 13.4 Mns in Q2 FY24.

(3) Footfalls for IP correspond to Discharges

Cluster Split – India (Q2 FY25)

This considers owned/operated hospitals in India (excl. Jammu⁽¹⁾)




(1) Jammu facility reported operational revenues of INR 322 Mns and EBITDA of INR -4.3 Mns in Q2 FY25

(2) OP ARPP includes day care.

Profitability Snapshot – India Hospitals (Q2 FY25)


Excludes NHIC, NHIL, ATHMA & MEDHA (2)



EBITDA and EBITDA Margin⁽¹⁾

INR 'Mns







- (1) Denotes EBITDA for entire India hospitals business excluding NHIC, NHIL, ATHMA & MEDHA.
- (2) EBITDA for Q2 FY25 including NHIC, NHIL, ATHMA & MEDHA stood at INR 2,301 Mns (19.7%). EBITDA for NHIC and NHIL stood at -INR 137.5 Mns for Q2 FY25.
- (3) Q2 FY24 numbers is also adjusted for NHIC and ATHMA.


- (4) Consumable Expenses = Purchase of medical consumables, drugs and surgical equipment net of changes in inventories of medical consumables, drugs and surgical equipment
- (5) Doctors and Nurses = Employee benefits + Professional fees to doctors
- (6) Other Expenses = Overhead expenses + All other expenses
- (7) Effect of IND AS benefits is not considered

Operational Review – Cayman Islands







Operating Revenues



Q2 FY24







Figures in INR Mns, unless stated otherwise

Profit and Loss Statement⁽¹⁾

Particulars (INR Mns)	Q2 FY25	H1 FY25
Total Operating Revenue	14,000	27,410
Consumption	3,002	5,884
Doctors Expenses	2,453	4,811
Employee (Excluding Doctors) Expenses	2,820	5,584
Other Admin Expenses	2,640	5,007
Total Expenses	10.916	21,287
Other Income	236	471
EBITDA	3,320	6,594
Depreciation and Amortization	651	1,268
Finance Costs	351	691
Share of (loss)/profit of equity accounted investees	-	-
РВТ	2318	4,635
Tax Expense	330	632
PAT	1988	4003
Total Comprehensive Income	2,041	4,035

Key Balance Sheet Items⁽¹⁾

Particulars	30 th Sept 2024
Shareholder Equity	32,073
Total Borrowings	15,135
Lease Liability	1,897
Net Block + CWIP ⁽²⁾	33,532
Goodwill	1,181
Right to Use Assets	2,043
Net Receivables	5,426
Current Investments	8,568
Cash and Bank Balance	3,289


As on September 30th 2024, the Total Borrowings less Cash & Bank Balance and Investments was INR 2,684 Mn, representing a net debt to equity ratio of 0.08 (Out of which, debt worth US\$ 81.5 Mns is foreign currency denominated).


(1) Figures might not equal the reported numbers due to rounding off.

(2) Net Block includes non-cash government grant impact of INR 1,074 Mns, non-cash financial lease impact of INR 516 Mns and non-cash EPCG license impact of INR 215 Mns




INR Mns





Program running since September 2022 at select Bengaluru locations



Integrated Care now available at nine locations in Bangalore

Aditi Health Insurance piloted in Mysore and now expanded to Bangalore

* Includes NHIC (Clinics) only. ** Gross written premium of NHIL.

Digital Transformation Initiatives

Impact | Mobile Apps



- 50% in-patient documents reduced with mobile app
- Improved incident tracking and closure with Namah



- Reached peak OP digital volume of 80% in select units through the introduction of patient kiosks
- Crossed 250K monthly active
 users of NH patient app



Launch | New Products

• Outpatient Access-control pilot launched

 Automated vital check for Outpatients launched



- Peer-review and research modules in Radiology launched
- Improved scheduling and management of non-lab diagnostics launched



:=



- 10% reduction in lab and radiology reporting turnaround time
- Automated integration with thirdparty providers and labs



GTM | Athma

- **750 Beds** across 4 facilities added in Q2 FY 24-25
- 850+ Beds in pipeline for H2



- Athma RIS-PACS rolled out completely in **17 units across India**
- Streamlined management healthcheck patients flow implemented




- 10 Clinics, 1 Hospital onboarded
- Pipeline set-up for Middle-east and South-East Asia underway




A Healthy Planet

By being conscious about impact on the environment, prioritizing consumption efficiency and resource optimization





As on 30th Sept 2024⁽¹⁾



Total Number of Shares 204,360,804

Key Dlls	Key Flls
Axis Asset Management	Simcah Partners LP
SBI Life Insurance Co. Ltd.	Franklin Templeton Investment Funds
ICICI Prudential Life Insurance Co. Ltd.	Government Pension Fund
Nippon Life India Asset Management	Vanguard Index Funds
Unifi Capital	Kuwait Investment Authority Fund



No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment.

Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India.

This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.

For further Information, please contact :

Mr. Nishant Singh	Mr. Vivek Agarwal
Vice President – Finance, Investor Relations, M&A	Senior Manager – Investor Relations, M&A
+91 8369353821	+91 9510756827
nishant.singh@narayanahealth.org	vivek.agarwal@narayanahealth.org

investorrelations@narayanahealth.org

